WNT4 and female reproductive organ cancer: Understanding how WNT4 signaling is dysregulated, by estrogen and genetic polymorphism in ILC vs. gynecologic cancers, offers new opportunities for defining tumor biology, precision therapeutics, and personalized cancer risk assessment.